Acacia

More than 4,000 unaccompanied immigrant children in California are at risk of losing their free legal representation. This situation arose after the nonprofit Acacia lost its federal contract on August 1.

Cytokinetics' drug Myqorzo met efficacy goals in a Phase 3 clinical trial for non-obstructive hypertrophic cardiomyopathy, a genetic heart disease. The trial's success could expand treatment eligibility and boost peak sales to $5 billion annually. Myqorzo is already in commercial launch for a more severe form of the disease.